drugset
drugset / Trial / NCT03445650

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

NCT03445650 ↗

Phase 3 Completed 11 enrolled Aldeyra Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects with Sjögren-Larsson Syndrome (SLS).

Timeline

Start
2018-07-18
Primary completion
2020-01-18
Completion
2020-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Reproxalap Other / unclassified 1 % Topical

Indications

Sjogren-Larsson syndrome